Merck & Co Inc Says FDA Sets PDUFA Date Of June 19, 2026 For Welireg And Keytruda

Feb 28 (Reuters) - Merck & Co Inc MRK.N:

• KEYTRUDA® (PEMBROLIZUMAB) PLUS WELIREG® (BELZUTIFAN) GIVEN AS ADJUVANT THERAPY REDUCED THE RISK OF DISEASE RECURRENCE OR DEATH BY 28% COMPARED TO KEYTRUDA MONOTHERAPY IN CERTAIN PATIENTS WITH EARLIER-STAGE RENAL CELL CARCINOMA (RCC)

• MERCK & CO INC - KEYTRUDA PLUS WELIREG REDUCES RISK OF RECURRENCE OR DEATH BY 28%

• MERCK & CO INC - FDA ACCEPTS PRIORITY REVIEW FOR WELIREG AND KEYTRUDA COMBINATION

• MERCK & CO INC - FDA SETS PDUFA DATE OF JUNE 19, 2026 FOR WELIREG AND KEYTRUDA